spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

rfxcel Covers the Cost of EMVO Onboarding Fees


May 23, 2018 - San Ramon, CA – rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.

Manufacturers who wish to participate in this great opportunity should contact rfxcel (eu@rfxcel.com) for details of the solution and terms of the offer. They then simply need to name rfxcel as their Gateway Provider when registering on the EMVO portal (https://emvo-medicines.eu/pharmaceutical-companies) before June 15th 2018. When we conclude a software contract, the cost of the EMVO fee will be absorbed by rfxcel as a discount.

With EMVO onboarding fees increasing by 50% after June 15th 2018, rfxcel is taking a significant step in helping EMVO to accelerate its onboarding programme and MAHs to meet their requirements under the Falsified Medicines Directive in a timely manner.

rfxcel provides a full-service, fixed price approach that gets MAHs ready to exchange data with EMVO quickly and efficiently. We manage the end to end process from EMVO onboarding to connection, reporting and interaction with business partners such as contract manufacturers (CMOs). This enables even very small MAH companies to comply with FMD obligations with minimum resource and cost impact.

“Our initiative to cover the cost of the EMVO onboarding fee, paired with our rapid, full-service implementation, provides a great opportunity to MAHs who need move quickly. With rfxcel they also avoid the hidden costs and additional resources required by other solution providers to onboard their trading partners”, said Mark Davison, rfxcel Senior Director of Operations Europe.

To learn more about the requirements surrounding the European Union’s Falsified Medicines Directive (FMD) or rfxcel’s solutions to meet these needs, please contact us.

*The offer relates to EMVO (one-time) onboarding fees only. It does not include any initial or annual fees that may be payable to national medicine verification organisations (NMVOs).

For more information contact us:
Herb Wong, VP Marketing
hwong@rfxcel.com
rfxcel.com

About rfxcel:

rfxcel is the leading provider of SaaS-based track and trace solutions, with offices worldwide and EU headquarters in the United Kingdom. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Quanticate Partners with CluePoints to Offer Data Quality Oversight capabilities

Quanticate, a data-focused clinical research organisation (CRO), has announced that it has partnered with CluePoints as part of its new Data Quality Oversight service.
More info >>


White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

Industry Events

4th Annual Genome Editing Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 4thAnnual Genome Editing Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement